Pharmacoeconomic analysis of everolimus immunosuppressive therapy for <i>de novo</i> kidney transplant recipients in Russia

QR Code

Pharmacoeconomic analysis of everolimus immunosuppressive therapy for <i>de novo</i> kidney transplant recipients in Russia

Currently, patients after kidney transplantation can receive mycophenolate mofetil (MPM), mycophenolic acid (MPA), cyclosporine (CSA) and tacrolimus (TAC) through the Federal High-cost Nosologies Program (VZN) in Russia. Use of everolimus (EVL) in combination with a reduced dose of calcineurin inhib...

Full description

Saved in:

Bibliographic Details
Main Authors:	N. A. Avxentyev, E. V. Derkach, E. I. Prokopenko
Format:	Article
Language:	Russian
Published:	Federal Research Center of Transplantology and Artificial Organs named after V.I.Shumakov 2019-05-01
Series:	Вестник трансплантологии и искусственных органов
Subjects:	kidney transplantation immunosuppressive therapy everolimus mycophenolic acid cyclosporine tacrolimus cost minimization budget impact analysis
Online Access:	https://journal.transpl.ru/vtio/article/view/986
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

PHARMACOECONOMIC ANALYSIS OF EVEROLIMUS IMMUNOSUPRESSIVE THERAPY AFTER RENAL TRANSPLANTATION
by: M. V. Avxentyeva, et al.
Published: (2015-06-01)

FIRST EXPERIENCE IN SYSTEMIC ADMINISTRATION OF EVEROLIMUS IN RENAL TRANSPLANTATION FROM EXPANDED CRITERIA DONORS IN RUSSIAN FEDERATION
by: I. V. Uliyankina, et al.
Published: (2017-01-01)

Clinical laboratory aspects of one-component immunosuppression during liver transplantation
by: M. Sh. Khubutia, et al.
Published: (2018-08-01)

Systematic Review of Pharmacogenetics of Immunosuppressants in Heart Transplantation
by: Juan Eduardo Megías-Vericat, et al.
Published: (2025-06-01)

Efficiency of late conversion from mycophenolate mofetil to everolimus in kidney graft recipients with posttransplant malignancy
by: I. G. Kim, et al.
Published: (2018-01-01)

Analysis of early use of everolimus with low-dose calcineurin inhibitors in kidney transplant recipient
by: I. G. Kim, et al.
Published: (2019-10-01)

EVEROLIMUS IN DE NOVO RENAL TRANSPLANT RECIPIENTS
by: E. I. Prokopenko
Published: (2010-06-01)

Changes in glomerular filtration rate in liver recipients after reduced exposure to calcineurin inhibitors with concomitant everolimus administration within the first year after immunosuppression conversion
by: V. E. Syutkin, et al.
Published: (2022-01-01)

Everolimus in clinical practice after liver transplantation: a single-center experience
by: O. A. Gerasimova, et al.
Published: (2017-06-01)

Use of tacrolimus to prevent acute kidney graft rejection in sensitized patients
by: O. N. Rzhevskaya, et al.
Published: (2018-08-01)

An acute episode of rhabdomyolysis associated with everolimus and cabergoline intake in a postpartum kidney recipient
by: B. I. Yaremin, et al.
Published: (2017-12-01)

Efficacy and Long-Term Outcomes of Tacrolimus versus Cyclophosphamide and Mycophenolate Mofetil in the Management of Pediatric IgA Vasculitis Nephritis: A Cohort Study in Single-Center
by: Han Y, et al.
Published: (2025-07-01)

The role of calcineurin inhibitors in the progression of hepatocellular carcinoma after liver transplantation
by: O. D. Olisov, et al.
Published: (2022-09-01)

Evaluation of the results of treatment of kidney recipients at the outpatient stage against the background of minimizing immunosuppressive therapy
by: E. V. Parabina, et al.
Published: (2023-10-01)

The effect of early everolimus administration on the renal function while reducing the dosage of calcineurin inhibitors in liver transplant recipients in a long-term follow-up
by: V. E. Syutkin, et al.
Published: (2021-06-01)

CORNEAL GRAFT REJECTION AFTER KERATOPLASTY
by: S. V. Trufanov, et al.
Published: (2017-10-01)

Personalized dosing protocol for extended-release tacrolimus in kidney transplant recipients in the early postoperative period
by: A. V. Shabunin, et al.
Published: (2023-04-01)

Risk Prediction and Management of BKPyV-DNAemia in Kidney Transplant Recipients: A Multicenter Analysis of Immunosuppressive Strategies
by: Jin-Myung Kim, et al.
Published: (2025-07-01)

Effect of Tegoprazan on Tacrolimus and Mycophenolate Levels in Kidney Transplant Recipients: A Randomized Controlled Study Using a Smart Trial Platform
by: Seong-Wook Lee, et al.
Published: (2025-06-01)

Complete regression of generalized plasmacytoma of lymph nodes in a liver transplant recipient during the conversion of immunosuppressive therapy from tacrolimus to everolimus
by: V. E. Syutkin, et al.
Published: (2021-09-01)

Long-term use of everolimus as a component of immunosuppressive therapy in liver transplant recipients
by: M. Sh Khubutia, et al.
Published: (2016-01-01)

Approaches to correction of immunosuppressive therapy in chronic nephrotoxicity of calcineurin inhibitors
by: E. S. Stolyarevich, et al.
Published: (2018-08-01)

Pharmacoeconomic analysis of using drugs containing mycophenolic acid in kidney transplant recipients in the context of domestic pharmaceutical market
by: V. N. Lesovoy, et al.
Published: (2015-08-01)

Renal function in liver recipients: in-depth analysis of data from the Local Scientific Transplant Registry of the Burnasyan Federal Medical Biophysical Center
by: A. I. Sushkov, et al.
Published: (2025-06-01)

The Effect of Cyclosporine and Tacrolimus Systemic Therapy on Gingival Overgrowth in Renal Transplant Patients Aged Between 18-70 Years in Erbil City-Iraq
by: Aveen A. Jalal
Published: (2025-06-01)

Extrahepatic malignant neoplasms after liver transplantation: the experience of a single transplant center
by: O. A. Gerasimova, et al.
Published: (2020-02-01)

EVEROLIMUS FOR KAPOSI'S SARCOMA TREATMENT AFTER KIDNEY TRANSPLANTATION
by: I. V. Alexandrov, et al.
Published: (2015-05-01)

Refractory Infantyl Chylous Ascites Treatment by Everolimus
by: Masallah BARAN, et al.
Published: (2025-06-01)

Relevant Issues of Planning Bioequivalence Studies of Drugs with a Narrow Therapeutic Range
by: D. P. Romodanovsky
Published: (2020-09-01)

A case of rhabdomyolysis after atorvastatin therapy of a liver transplant recipient receiving immunosuppressive therapy with cyclosporine
by: A. V. Shabunin, et al.
Published: (2021-06-01)

The experience of use of everolimus in patients having undergone to orthotopic liver transplantation
by: V. E. Syutkin, et al.
Published: (2018-08-01)

Effectiveness of myocarditis therapy depending on the diagnosis approach (with or without myocardial biopsy)
by: O. V. Blagova, et al.
Published: (2021-05-01)

On the interchangeability of calcineurine inhibitors
by: K. E. Zatolochina, et al.
Published: (2018-02-01)

THE USE OF EVEROLIMUS IN KIDNEY TRANSPLANTATION FROM EXPANDED CRITERIA DONORS
by: I. V. Ulyankina, et al.
Published: (2009-06-01)

The ability of Mycophenolate Mofetil to induce chromosome aberration and DNA damage in Mus Musculus Mice
by: RUIDA WATHEQ NEAMA, et al.
Published: (2019-12-01)

A case of sternal osteomyelitis during treatment with everolimus for recurrent breast cancer
by: Kaori Abe, et al.
Published: (2022-01-01)

Clinical Profile of Pediatric Patients with Steroid-resistant Nephrotic Syndrome Treated by Cyclophosphamide, Cyclosporin A, Mycophenolate Mofetile and Tacrolimus in Hasan Sadikin General Hospital
by: Ahmedz Widiasta, et al.
Published: (2024-03-01)

COVID-19 Pneumonia in Patients with Chronic Myocarditis (HBV-Associated with InfarctLike Debute): Specifics of the Diseases Course, the Role of the Basic Therapy (Part II)
by: O. V. Blagova, et al.
Published: (2020-11-01)

Juvenile Localized Scleroderma. Questions of Treatment
by: Rinat K. Raupov, et al.
Published: (2020-08-01)

Profile of everolimus in the treatment of tuberous sclerosis complex: an evidence-based review of its place in therapy
by: Capal J, et al.
Published: (2016-08-01)